Tag: Guto Bebb

The below Parliamentary question was asked by Guto Bebb on 2016-01-18.

To ask the Secretary of State for Health, what information his Department holds on the effects of nivolumab on one year survival rates for lung cancer.

George Freeman

Nivolumab is currently marketed in the European Union under the brand name Opdivo.

The data available when Opdivo was licensed in 2015 indicated overall survival among patients given the product was around nine months, whereas among the patients given docetaxel, another cancer medicine, it was six months.

The below Parliamentary question was asked by Guto Bebb on 2016-03-14.

To ask the Secretary of State for Work and Pensions, if he will make it his Department’s policy to accept data protection forms relating to queries arising from hon. Members’ casework by email.

Justin Tomlinson

DWP current email policy states “this policy does not change existing rules on communications with Members of Parliament (MPs) and when responding to customer complaints (handled by the Independent Case Examiner) where the MP or complainant has requested a response by email”.

A Member is the data controller for all personal data handled by their own office and must be registered with the Information Commissioners Office in accordance with the following guidance.

http://www.parliament.uk/documents/upload/advice-for-members-offices.pdf

“

The below Parliamentary question was asked by Guto Bebb on 2015-10-30.

To ask the Secretary of State for Health, what representations he has received on the availability of comparative information on and screening for prostate cancer.

Jane Ellison

The UK National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation. In 2010, the UK NSC recommended against a screening programme for prostate cancer as there was no clear evidence that the benefit to screen for prostate cancer outweighed the harms. The UK NSC re-affirmed this decision in 2012 and is in the process of reviewing this policy currently.

The School of Health and Related Research at the University of Sheffield performed an option appraisal for the UK NSC based on the latest trial evidence for screening for prostate cancer in 2013. A number of screening strategies were considered including annual screening in men aged 50 to 74 years. The overall survival benefit with all strategies was small and outweighed by the harms of over diagnosis and the adverse effects of over treatment.

Public Health England (PHE) ran a local pilot campaign for six weeks in 2014, specifically targeting prostate cancer within Black African-Caribbean men, because of their significantly increased risk of developing prostate cancer. The campaign ran in six London boroughs. In addition, PHE will be running a national campaign on “Blood in Pee” in early 2016. This is primarily aimed at bladder and kidney cancer but blood in the urine can also be a sign of prostate cancer.

The below Parliamentary question was asked by Guto Bebb on 2015-10-30.

To ask the Secretary of State for Health, what steps his Department has taken to increase awareness of prostate cancer.

Jane Ellison

The UK National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation. In 2010, the UK NSC recommended against a screening programme for prostate cancer as there was no clear evidence that the benefit to screen for prostate cancer outweighed the harms. The UK NSC re-affirmed this decision in 2012 and is in the process of reviewing this policy currently.

The School of Health and Related Research at the University of Sheffield performed an option appraisal for the UK NSC based on the latest trial evidence for screening for prostate cancer in 2013. A number of screening strategies were considered including annual screening in men aged 50 to 74 years. The overall survival benefit with all strategies was small and outweighed by the harms of over diagnosis and the adverse effects of over treatment.

Public Health England (PHE) ran a local pilot campaign for six weeks in 2014, specifically targeting prostate cancer within Black African-Caribbean men, because of their significantly increased risk of developing prostate cancer. The campaign ran in six London boroughs. In addition, PHE will be running a national campaign on “Blood in Pee” in early 2016. This is primarily aimed at bladder and kidney cancer but blood in the urine can also be a sign of prostate cancer.

The below Parliamentary question was asked by Guto Bebb on 2015-10-30.

To ask the Secretary of State for Health, what assessment he has made of the effect of an annual screening programme on early detection of prostate cancer.

Jane Ellison

The UK National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation. In 2010, the UK NSC recommended against a screening programme for prostate cancer as there was no clear evidence that the benefit to screen for prostate cancer outweighed the harms. The UK NSC re-affirmed this decision in 2012 and is in the process of reviewing this policy currently.

The School of Health and Related Research at the University of Sheffield performed an option appraisal for the UK NSC based on the latest trial evidence for screening for prostate cancer in 2013. A number of screening strategies were considered including annual screening in men aged 50 to 74 years. The overall survival benefit with all strategies was small and outweighed by the harms of over diagnosis and the adverse effects of over treatment.

Public Health England (PHE) ran a local pilot campaign for six weeks in 2014, specifically targeting prostate cancer within Black African-Caribbean men, because of their significantly increased risk of developing prostate cancer. The campaign ran in six London boroughs. In addition, PHE will be running a national campaign on “Blood in Pee” in early 2016. This is primarily aimed at bladder and kidney cancer but blood in the urine can also be a sign of prostate cancer.

The below Parliamentary question was asked by Guto Bebb on 2015-10-30.

To ask the Secretary of State for Health, what steps his Department has taken to support prostate cancer awareness campaigns and screening programmes.

Jane Ellison

The UK National Screening Committee (UK NSC) advises Ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation. In 2010, the UK NSC recommended against a screening programme for prostate cancer as there was no clear evidence that the benefit to screen for prostate cancer outweighed the harms. The UK NSC re-affirmed this decision in 2012 and is in the process of reviewing this policy currently.

The School of Health and Related Research at the University of Sheffield performed an option appraisal for the UK NSC based on the latest trial evidence for screening for prostate cancer in 2013. A number of screening strategies were considered including annual screening in men aged 50 to 74 years. The overall survival benefit with all strategies was small and outweighed by the harms of over diagnosis and the adverse effects of over treatment.

Public Health England (PHE) ran a local pilot campaign for six weeks in 2014, specifically targeting prostate cancer within Black African-Caribbean men, because of their significantly increased risk of developing prostate cancer. The campaign ran in six London boroughs. In addition, PHE will be running a national campaign on “Blood in Pee” in early 2016. This is primarily aimed at bladder and kidney cancer but blood in the urine can also be a sign of prostate cancer.

The below Parliamentary question was asked by Guto Bebb on 2015-10-20.

To ask the Secretary of State for Foreign and Commonwealth Affairs, what reports he has received on the involvement of Palestinian terror groups in the recent violence in Israel and the West Bank.

Mr Tobias Ellwood

While it appears that the majority of the attacks seen in Israel and the Occupied Palestinian Territories in recent weeks have been carried out by individuals, without direct organisation from political or terrorist groups, we have seen media reports of Palestinian terrorist groups claiming responsibility for some recent attacks, praising attacks, and appearing to incite further violence. We condemn all the terrorist attacks, as I made clear in the House on 20 October, and in my statement on 13 October.

The below Parliamentary question was asked by Guto Bebb on 2015-10-09.

To ask Mr Chancellor of the Exchequer, what assessment his Department has made of the effect on SMEs of a move from the flat rate scheme for VAT to the general rate.

Mr David Gauke

HMRC estimates that, on average, businesses moving from the flat rate scheme to standard VAT accounting incur extra administrative costs of £45 per year.

The below Parliamentary question was asked by Guto Bebb on 2015-10-09.

To ask Mr Chancellor of the Exchequer, whether his Department has made an assessment of the potential benefits of increasing the turnover threshold at which it becomes necessary to adopt the general rate for VAT for the tourism industry.

Mr David Gauke

No such assessment has been made. The Government has chosen to maintain the highest VAT registration threshold in the EU. EU law allows us to increase the threshold in line with inflation, and it has therefore increased to £82,000 with effect from 1 April 2015.

The below Parliamentary question was asked by Guto Bebb on 2015-10-09.

To ask Mr Chancellor of the Exchequer, when he plans to respond to the recommendations of the Treasury Committee’s report, Conduct and competition in SME lending, published on 16 March 2015.

Harriett Baldwin

The Parliament, and its then Treasury Select Committee, dissolved shortly after this report was published and HM Treasury was not able to prepare a response before dissolution.

HM Treasury is considering the Committee’s recommendations and will be responding to the new Committee in due course.